Potentially, the intestinal tumour resistance of the Mbd2−/− mouse is due to an enhanced anti‐tumourigenic Th1/Ifng response, a loss of Mbd2 epigenetic regulation within the intestinal epithelia or a combination of both. Here, MBD2 is linked to intestinal neoplasm.